Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03), FiscalAI reports. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.32% and a negative net margin of 55,866.82%.
Perspective Therapeutics Stock Up 1.5%
Shares of NYSEAMERICAN CATX opened at $0.80 on Wednesday. The stock has a fifty day moving average price of $2.24 and a 200 day moving average price of $3.47. Perspective Therapeutics has a 1-year low of $0.78 and a 1-year high of $6.16.
Analyst Upgrades and Downgrades
CATX has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday. Royal Bank Of Canada cut shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $14.00 to $4.00 in a report on Monday, October 26th. Bank of America reduced their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Finally, Piper Sandler lowered their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.10.
View Our Latest Analysis on CATX
About Perspective Therapeutics
Perspective Therapeutics, Inc. is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue. The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.
Further Reading
- Five stocks we like better than Perspective Therapeutics
- 3 Stocks Wall Street Likes More Than the Market Does
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
